ID: ALA201235

Max Phase: Preclinical

Molecular Formula: C23H19NO3S

Molecular Weight: 389.48

Molecule Type: Small molecule

Representations

Canonical SMILES:  Oc1nc2sc3c(c2c(O)c1-c1cccc(Oc2ccccc2)c1)CCCC3

Standard InChI:  InChI=1S/C23H19NO3S/c25-21-19(14-7-6-10-16(13-14)27-15-8-2-1-3-9-15)22(26)24-23-20(21)17-11-4-5-12-18(17)28-23/h1-3,6-10,13H,4-5,11-12H2,(H2,24,25,26)

Standard InChI Key:  NJXSJKRJWCTNFK-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 389.48

Molecular Weight (Monoisotopic): 389.1086

AlogP: 6.05

#Rotatable Bonds: 3

Polar Surface Area: 62.58

Molecular Species: NEUTRAL

HBA: 5

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 4

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 9.57

CX Basic pKa:

CX LogP: 6.72

CX LogD: 6.72

Aromatic Rings: 4

Heavy Atoms: 28

QED Weighted: 0.45

Np Likeness Score: -0.91

References

1. Buchstaller HP, Siebert CD, Steinmetz R, Frank I, Berger ML, Gottschlich R, Leibrock J, Krug M, Steinhilber D, Noe CR..  (2006)  Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor.,  49  (3): [PMID:16451052] [10.1021/jm0503493]

Source

Source(1):

• Scientific Literature